Association between baseline lactate dehydrogenase and immune-related adverse events among patients with melanoma varies by tumor stage at immune checkpoint inhibitor initiation
Gespeichert in:
| Veröffentlicht in: | Journal of the American Academy of Dermatology 2023-12, Vol.89 (6), p.1264-1268 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1268 |
|---|---|
| container_issue | 6 |
| container_start_page | 1264 |
| container_title | Journal of the American Academy of Dermatology |
| container_volume | 89 |
| creator | Pan, Catherina X. Lau, William C. Kim, Daniel Y. Lau, Charles B. Rowley, Rachael Kanwar, Ruhi LeBoeuf, Nicole R. Nambudiri, Vinod E. |
| description | |
| doi_str_mv | 10.1016/j.jaad.2023.07.1029 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2850313740</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0190962223024222</els_id><sourcerecordid>2850313740</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-e7a5270425e1b76f6cb4c8e2b671675f8dbb3ab6118fbe96e45665248cfe959b3</originalsourceid><addsrcrecordid>eNp9kU1vEzEQhi1ERUPLL0BCPnLZYHt37d0Dh6riS6rEpT1b_phNHNZ2sL2p8rP4hzgkcOQ08swz78z4RegtJWtKKP-wW--UsmtGWLsmoubY-AKtKBlFw8UgXqIVoSNpRs7YNXqd844QMnateIWuW9FzxglZoV93OUfjVHExYA3lGaBGlWF2AfCsTFEFsIXt0aa4gVArWAWLnfdLgCbBXOsWK3uAVEtwgFAyVj6GDd5X1T_PZ1e22Fc0RK_wQSUHGesjLouPCeeiNlW0XDSx2YL5sY8u1EzYOu1KhVxw5bzlLbqa1JzhzSXeoKfPnx7vvzYP3798u797aEzbj6UBoXomSMd6oFrwiRvdmQGY5oJy0U-D1bpVmlM6TBpGDl3Pec-6wUww9qNub9D7s-4-xZ8L5CK9ywbmegXEJUs29KSlrehIRdszalLMOcEk98l5lY6SEnnySu7kySt58koSIU9e1a53lwGL9mD_9fw1pwIfzwDUMw8OksymfqgB6xKYIm10_x3wG5ySqxY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2850313740</pqid></control><display><type>article</type><title>Association between baseline lactate dehydrogenase and immune-related adverse events among patients with melanoma varies by tumor stage at immune checkpoint inhibitor initiation</title><source>Elsevier ScienceDirect Journals</source><creator>Pan, Catherina X. ; Lau, William C. ; Kim, Daniel Y. ; Lau, Charles B. ; Rowley, Rachael ; Kanwar, Ruhi ; LeBoeuf, Nicole R. ; Nambudiri, Vinod E.</creator><creatorcontrib>Pan, Catherina X. ; Lau, William C. ; Kim, Daniel Y. ; Lau, Charles B. ; Rowley, Rachael ; Kanwar, Ruhi ; LeBoeuf, Nicole R. ; Nambudiri, Vinod E.</creatorcontrib><identifier>ISSN: 0190-9622</identifier><identifier>EISSN: 1097-6787</identifier><identifier>DOI: 10.1016/j.jaad.2023.07.1029</identifier><identifier>PMID: 37562600</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>CTLA-4 inhibitors ; hepatobiliary ; immune checkpoint inhibitors ; immune-related adverse events ; immunosuppression ; immunotherapy ; lactate dehydrogenase ; liver ; melanoma ; PD-1 inhibitors ; toxicity</subject><ispartof>Journal of the American Academy of Dermatology, 2023-12, Vol.89 (6), p.1264-1268</ispartof><rights>2023 American Academy of Dermatology, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-e7a5270425e1b76f6cb4c8e2b671675f8dbb3ab6118fbe96e45665248cfe959b3</citedby><cites>FETCH-LOGICAL-c359t-e7a5270425e1b76f6cb4c8e2b671675f8dbb3ab6118fbe96e45665248cfe959b3</cites><orcidid>0000-0002-4403-8508</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0190962223024222$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37562600$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pan, Catherina X.</creatorcontrib><creatorcontrib>Lau, William C.</creatorcontrib><creatorcontrib>Kim, Daniel Y.</creatorcontrib><creatorcontrib>Lau, Charles B.</creatorcontrib><creatorcontrib>Rowley, Rachael</creatorcontrib><creatorcontrib>Kanwar, Ruhi</creatorcontrib><creatorcontrib>LeBoeuf, Nicole R.</creatorcontrib><creatorcontrib>Nambudiri, Vinod E.</creatorcontrib><title>Association between baseline lactate dehydrogenase and immune-related adverse events among patients with melanoma varies by tumor stage at immune checkpoint inhibitor initiation</title><title>Journal of the American Academy of Dermatology</title><addtitle>J Am Acad Dermatol</addtitle><subject>CTLA-4 inhibitors</subject><subject>hepatobiliary</subject><subject>immune checkpoint inhibitors</subject><subject>immune-related adverse events</subject><subject>immunosuppression</subject><subject>immunotherapy</subject><subject>lactate dehydrogenase</subject><subject>liver</subject><subject>melanoma</subject><subject>PD-1 inhibitors</subject><subject>toxicity</subject><issn>0190-9622</issn><issn>1097-6787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kU1vEzEQhi1ERUPLL0BCPnLZYHt37d0Dh6riS6rEpT1b_phNHNZ2sL2p8rP4hzgkcOQ08swz78z4RegtJWtKKP-wW--UsmtGWLsmoubY-AKtKBlFw8UgXqIVoSNpRs7YNXqd844QMnateIWuW9FzxglZoV93OUfjVHExYA3lGaBGlWF2AfCsTFEFsIXt0aa4gVArWAWLnfdLgCbBXOsWK3uAVEtwgFAyVj6GDd5X1T_PZ1e22Fc0RK_wQSUHGesjLouPCeeiNlW0XDSx2YL5sY8u1EzYOu1KhVxw5bzlLbqa1JzhzSXeoKfPnx7vvzYP3798u797aEzbj6UBoXomSMd6oFrwiRvdmQGY5oJy0U-D1bpVmlM6TBpGDl3Pec-6wUww9qNub9D7s-4-xZ8L5CK9ywbmegXEJUs29KSlrehIRdszalLMOcEk98l5lY6SEnnySu7kySt58koSIU9e1a53lwGL9mD_9fw1pwIfzwDUMw8OksymfqgB6xKYIm10_x3wG5ySqxY</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Pan, Catherina X.</creator><creator>Lau, William C.</creator><creator>Kim, Daniel Y.</creator><creator>Lau, Charles B.</creator><creator>Rowley, Rachael</creator><creator>Kanwar, Ruhi</creator><creator>LeBoeuf, Nicole R.</creator><creator>Nambudiri, Vinod E.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4403-8508</orcidid></search><sort><creationdate>20231201</creationdate><title>Association between baseline lactate dehydrogenase and immune-related adverse events among patients with melanoma varies by tumor stage at immune checkpoint inhibitor initiation</title><author>Pan, Catherina X. ; Lau, William C. ; Kim, Daniel Y. ; Lau, Charles B. ; Rowley, Rachael ; Kanwar, Ruhi ; LeBoeuf, Nicole R. ; Nambudiri, Vinod E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-e7a5270425e1b76f6cb4c8e2b671675f8dbb3ab6118fbe96e45665248cfe959b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>CTLA-4 inhibitors</topic><topic>hepatobiliary</topic><topic>immune checkpoint inhibitors</topic><topic>immune-related adverse events</topic><topic>immunosuppression</topic><topic>immunotherapy</topic><topic>lactate dehydrogenase</topic><topic>liver</topic><topic>melanoma</topic><topic>PD-1 inhibitors</topic><topic>toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pan, Catherina X.</creatorcontrib><creatorcontrib>Lau, William C.</creatorcontrib><creatorcontrib>Kim, Daniel Y.</creatorcontrib><creatorcontrib>Lau, Charles B.</creatorcontrib><creatorcontrib>Rowley, Rachael</creatorcontrib><creatorcontrib>Kanwar, Ruhi</creatorcontrib><creatorcontrib>LeBoeuf, Nicole R.</creatorcontrib><creatorcontrib>Nambudiri, Vinod E.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pan, Catherina X.</au><au>Lau, William C.</au><au>Kim, Daniel Y.</au><au>Lau, Charles B.</au><au>Rowley, Rachael</au><au>Kanwar, Ruhi</au><au>LeBoeuf, Nicole R.</au><au>Nambudiri, Vinod E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between baseline lactate dehydrogenase and immune-related adverse events among patients with melanoma varies by tumor stage at immune checkpoint inhibitor initiation</atitle><jtitle>Journal of the American Academy of Dermatology</jtitle><addtitle>J Am Acad Dermatol</addtitle><date>2023-12-01</date><risdate>2023</risdate><volume>89</volume><issue>6</issue><spage>1264</spage><epage>1268</epage><pages>1264-1268</pages><issn>0190-9622</issn><eissn>1097-6787</eissn><cop>United States</cop><pub>Elsevier Inc</pub><pmid>37562600</pmid><doi>10.1016/j.jaad.2023.07.1029</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-4403-8508</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0190-9622 |
| ispartof | Journal of the American Academy of Dermatology, 2023-12, Vol.89 (6), p.1264-1268 |
| issn | 0190-9622 1097-6787 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2850313740 |
| source | Elsevier ScienceDirect Journals |
| subjects | CTLA-4 inhibitors hepatobiliary immune checkpoint inhibitors immune-related adverse events immunosuppression immunotherapy lactate dehydrogenase liver melanoma PD-1 inhibitors toxicity |
| title | Association between baseline lactate dehydrogenase and immune-related adverse events among patients with melanoma varies by tumor stage at immune checkpoint inhibitor initiation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T21%3A29%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20baseline%20lactate%20dehydrogenase%20and%20immune-related%20adverse%20events%20among%20patients%20with%20melanoma%20varies%20by%20tumor%20stage%20at%20immune%20checkpoint%20inhibitor%20initiation&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Dermatology&rft.au=Pan,%20Catherina%20X.&rft.date=2023-12-01&rft.volume=89&rft.issue=6&rft.spage=1264&rft.epage=1268&rft.pages=1264-1268&rft.issn=0190-9622&rft.eissn=1097-6787&rft_id=info:doi/10.1016/j.jaad.2023.07.1029&rft_dat=%3Cproquest_cross%3E2850313740%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2850313740&rft_id=info:pmid/37562600&rft_els_id=S0190962223024222&rfr_iscdi=true |